Analysts Set Expectations for MiMedx Group Q1 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Stock analysts at Northland Capmk issued their Q1 2025 EPS estimates for shares of MiMedx Group in a report issued on Friday, December 27th. Northland Capmk analyst C. Byrnes forecasts that the company will post earnings per share of $0.05 for the quarter. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS and Q4 2025 earnings at $0.09 EPS.

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group currently has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Up 1.5 %

Shares of MDXG opened at $9.62 on Monday. The firm has a market cap of $1.41 billion, a P/E ratio of 17.49 and a beta of 1.98. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14. The firm’s 50-day simple moving average is $8.51 and its 200 day simple moving average is $7.20.

Institutional Trading of MiMedx Group

Institutional investors have recently bought and sold shares of the business. Harbor Capital Advisors Inc. grew its holdings in shares of MiMedx Group by 299.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after purchasing an additional 770,744 shares in the last quarter. Millennium Management LLC grew its stake in MiMedx Group by 339.9% during the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock worth $6,164,000 after buying an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after buying an additional 413,443 shares in the last quarter. Paradigm Capital Management Inc. NY increased its holdings in MiMedx Group by 6.6% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after buying an additional 258,700 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of MiMedx Group by 265.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after buying an additional 215,995 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.